← Back to Home

Seeking Diagnostic Clues in the Cell Nucleus: Roche Launches BAP1 Tissue Test for Mesothelioma

Limited biopsy tissue must reveal both where a tumor originated and whether it is malignant. Roche’s newly launched automated staining test adds a tool for differentiating mesothelioma while aiming to preserve more tissue for subsequent molecular analysis.

By SURL BioNews

A small tissue sample often has to answer several questions: Is this benign proliferation or cancer? If it is cancer, what type of cell did it originate from? For patients who may have mesothelioma, these assessments are particularly important. On October 28, Roche announced the global launch of the VENTANA BAP1 (SP527) immunohistochemistry assay to help pathologists distinguish mesothelioma from other malignancies and benign tissue changes.

Mesothelioma arises in the mesothelial tissue covering internal organs or lining body cavities, commonly in the pleura. During diagnosis, physicians need staining markers as well as cellular morphology to help determine whether a lesion is mesothelial in origin and whether it has malignant features. Other cancers, such as lung cancer, involving the same sites further complicate the differential diagnosis.

The new test uses a ready-to-use antibody reagent for automated staining, with the key assessment being whether BAP1 protein expression is lost within cell nuclei. BAP1 is associated with tumor-suppressor function; in proliferative lesions already confirmed to be mesothelial in origin, loss of nuclear expression can provide evidence supporting malignancy. Roche noted that interpretation still requires mesothelial lineage markers such as WT1 and calretinin to bring the different clues together.

This also means that a single staining result cannot address every aspect of diagnosis. Existing pathology literature shows that BAP1 loss does not occur in all mesotheliomas, so retained expression alone cannot rule out malignancy. The launch announcement also did not provide the full validation sample size for the SP527 assay, sensitivity by subtype, or results of direct comparisons with current methods, leaving insufficient information to quantify how much it could improve diagnostic performance.

Another practical consideration is conserving specimens. In its October 29 report on the same development, SelectScience, citing Roche materials, stated that BAP1 can complement the recently launched VENTANA MTAP (SP530) and Claudin-4 (EP417) assays to help distinguish benign lesions and metastatic carcinomas. Roche maintains that appropriate use of these markers can help reduce tissue depletion caused by extensive antibody staining, preserving material for subsequent molecular sequencing; however, the announcement did not quantify the amount of tissue actually saved.

On the regulatory front, announcements from Roche’s global and US diagnostics divisions both stated that the product has been registered in the United States as a Class I in vitro diagnostic medical device and has received Class C medical device approval under the EU IVDR; US registration should not be described as the FDA having completed a review of the product’s performance. This launch gives pathology laboratories another automated tool, with its practical value depending on how it fits into existing interpretation workflows and whether it can achieve a better balance between diagnostic needs and specimen preservation.

References

  1. Roche
  2. Roche Diagnostics
  3. SelectScience